---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（20127118420728.PDF）的“原文Priscribing Information”为准
---------------------------------------------------------------
 部分中文Sclerosol处方资料（仅供参考）

Sclerosol Intrapleural Aerosol：治疗恶性胸腔积液; Bryan Corporation生产; 1998年1月批准上市

【通用名称】SCLEROSOL

【剂　　型】AEROSOL, METERED; INTRAPLEURAL

【规　　格】400MG/SPRAY

【活性成份】TALC

Sclerosol Intrapleural Aerosol
Company: Bryan Corporation
Approval Status: Approved January 1998
Treatment for: malignant pleural effusions
Areas: Cancer & Oncology; Respiratory

Adult Dosing & Uses
Dosing Forms & Strengths
intrapleural aerosol
•4g/25g propellant, delivers 400mg/second

sclerosing powder
•5g/100mL bottle

Malignant Pleural Effusion
Indicated as a sclerosing agent to decrease malignant pleural effusion recurrence in symptomatic patients

Administered intrapleurally via chest tube after adequate drainage of the effusion

Sclerosol: 4-8 g (1-2 canisters); deliver by manually pressing actuator button; distal end of the delivery tube should be pointed in several different directions, while short bursts are administered to distribute talc powder equally and extensively on all visceral and parietal pleural surfaces

Sterile Talc Powder: 5 g dissolved in 50-100 mL 0.9% NaCl

General Information
Sclerosol Intrapleural Aerosol has been approved for the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（20127118420728.PDF）的“原文Priscribing Information”为准
---------------------------------------------------------------